Jerusalem Pharmaceuticals Statistics

Total Valuation

Jerusalem Pharmaceuticals has a market cap or net worth of JOD 48.95 million. The enterprise value is 43.08 million.

Market Cap	48.95M
Enterprise Value	43.08M

Important Dates

The next estimated earnings date is Sunday, March 30, 2025.

Earnings Date	Mar 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Jerusalem Pharmaceuticals has 18.00 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	18.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.33%
Owned by Insiders (%)	42.26%
Owned by Institutions (%)	5.95%
Float	6.90M

Valuation Ratios

The trailing PE ratio is 16.76.

PE Ratio	16.76
Forward PE	n/a
PS Ratio	1.84
PB Ratio	1.03
P/TBV Ratio	1.07
P/FCF Ratio	27.12
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.13, with an EV/FCF ratio of 23.87.

EV / Earnings	14.80
EV / Sales	1.62
EV / EBITDA	8.13
EV / EBIT	10.32
EV / FCF	23.87

Financial Position

The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.03.

Current Ratio	4.19
Quick Ratio	2.95
Debt / Equity	0.03
Debt / EBITDA	0.24
Debt / FCF	0.70
Interest Coverage	52.93

Financial Efficiency

Return on equity (ROE) is 6.30% and return on invested capital (ROIC) is 5.38%.

Return on Equity (ROE)	6.30%
Return on Assets (ROA)	4.38%
Return on Capital (ROIC)	5.38%
Revenue Per Employee	50,673
Profits Per Employee	5,565
Employee Count	523
Asset Turnover	0.45
Inventory Turnover	1.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.79% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+0.79%
50-Day Moving Average	3.72
200-Day Moving Average	3.60
Relative Strength Index (RSI)	67.31
Average Volume (20 Days)	3,504

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jerusalem Pharmaceuticals had revenue of JOD 26.50 million and earned 2.91 million in profits. Earnings per share was 0.16.

Revenue	26.50M
Gross Profit	13.48M
Operating Income	4.16M
Pretax Income	4.00M
Net Income	2.91M
EBITDA	5.01M
EBIT	4.16M
Earnings Per Share (EPS)	0.16

Full Income Statement

Balance Sheet

The company has 7.79 million in cash and 1.26 million in debt, giving a net cash position of 6.53 million or 0.36 per share.

Cash & Cash Equivalents	7.79M
Total Debt	1.26M
Net Cash	6.53M
Net Cash Per Share	0.36
Equity (Book Value)	47.85M
Book Value Per Share	2.62
Working Capital	26.17M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.88 million and capital expenditures -1.07 million, giving a free cash flow of 1.80 million.

Operating Cash Flow	2.88M
Capital Expenditures	-1.07M
Free Cash Flow	1.80M
FCF Per Share	0.10

Full Cash Flow Statement

Margins

Gross margin is 50.88%, with operating and profit margins of 15.70% and 10.98%.

Gross Margin	50.88%
Operating Margin	15.70%
Pretax Margin	15.08%
Profit Margin	10.98%
EBITDA Margin	18.91%
EBIT Margin	15.70%
FCF Margin	6.81%

Dividends & Yields

This stock pays an annual dividend of 0.07, which amounts to a dividend yield of 2.61%.

Dividend Per Share	0.07
Dividend Yield	2.61%
Dividend Growth (YoY)	-33.42%
Years of Dividend Growth	2
Payout Ratio	40.58%
Buyback Yield	n/a
Shareholder Yield	2.61%
Earnings Yield	5.95%
FCF Yield	3.69%

Dividend Details

Stock Splits

The last stock split was on August 1, 2013. It was a forward split with a ratio of 1.4216864044.

Last Split Date	Aug 1, 2013
Split Type	Forward
Split Ratio	1.4216864044

Scores

Jerusalem Pharmaceuticals has an Altman Z-Score of 4.29.

Altman Z-Score	4.29
Piotroski F-Score	n/a